+ Watch ATRS
on My Watchlist
The Company develops, produces and markets pharmaceutical delivery products, including transdermal gels, oral fast melting tablets and reusable needle-free and disposable mini-needle injector systems.
With the Libigel wild card out of the way and Anturol on its way to being a commercial underperformer, I feel a lot safer re-upping my red thumb on Antares. It's clear that Antares is doomed just from the quality of commentators who feel compelled to pump it constantly on Seeking Alpha. I have no idea what goes through these jokers' heads as they churn out article after article until their desperation practically leaps from the computer screen. An enterprise value of 150M is high for a speculative pharma/device maker with 2.2M in product revenues last quarter and a neverending string of quarterly losses. The Libigel speculators have abandoned ship, but there's still enough hot air in this balloon to make a nice bang.
Hi ZzlangerhansAs I remember you had a green thumb on Bpax,Don't you you are wrong about this too!This cop. did the right thing of selling libo gel to Bpax and kept royalty outside US.Good management ,this very important in biotechnology small caps.I think the fair price fairPrice is between 4-6 $.
"I have no idea what goes through these jokers' heads as they churn out article after article until their desperation practically leaps from the computer screen."I was thinking the same thing about you. Wrong again.
Small biotech- big risk. AIS has many irons in the fire. Many thorough reviews on Seeking Alpha website.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions